Watchlist
VREX · Varex Imaging Corporation
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
Kill line
A daily close below $17.50 invalidates the completion-price thesis, retaining the research threshold published on 2026-09-03; it does not by itself establish that the merger has terminated.
Pick status
Open commitment catalyst in 12dscored if the kill line above fires How this is scored →Latest analysis and events for VREX —
As of 13 September 2026, the latest FrontierPicks analysis for Varex Imaging Corporation (VREX): Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
Kill line: A daily close below $17.50 invalidates the completion-price thesis, retaining the research threshold published on 2026-09-03; it does not by itself establish that the merger has terminated.
Next dated event on file: — catalyst in 12d.
Current Thesis
Varex Imaging Corporation’s thesis remains completion of Teledyne’s signed $18.90-per-share cash acquisition; payment settles the case, while a daily close below $17.50 invalidates the published price thesis. The companies announced the agreement on 2026-08-10 and guided completion to early calendar 2027. Joint announcement
The material change since the 2026-09-03 dossier is procedural: Varex filed its preliminary merger proxy on 2026-09-08. The previous concern about an absent proxy has therefore been resolved. The company’s filing list, checked on 2026-09-13, shows that document as its latest filing. Varex filing record
The narrative is saturated — an inference anchored in Sidoti’s 2026-08-10 downgrade to Neutral, Oppenheimer’s 2026-08-11 downgrade to Perform, and Benzinga’s 2026-08-14 weekly deal roundup. Those dated observations establish that the acquisition story is already broadly circulated; they do not measure investor crowding.
Bullish and bearish views on Varex Imaging Corporation
The model's bull view on Varex Imaging Corporation (VREX), in brief: Cash terms remove financing conditionality. The bear view: Regulatory scope is now explicit. The 2026-09-08 proxy identifies antitrust reviews in Austria, China, Germany, Japan, Saudi Arabia and Ukraine, plus United Kingdom investment screening. These are required approvals, not evidence of objections. Preliminary proxy Operating cash… Both cases follow in full.
Bull Case
- Cash terms remove financing conditionality. The 2026-08-10 agreement specifies $18.90 per share and contains no financing condition. This supports the completion case, although regulatory and stockholder conditions remain. Merger announcement filing
- The filing process has advanced. The 2026-09-08 preliminary proxy supersedes the missing-document concern in the 2026-09-03 dossier. It establishes progress toward solicitation, without establishing approval. SEC filing receipt
Bear Case
- Regulatory scope is now explicit. The 2026-09-08 proxy identifies antitrust reviews in Austria, China, Germany, Japan, Saudi Arabia and Ukraine, plus United Kingdom investment screening. These are required approvals, not evidence of objections. Preliminary proxy
- Operating cash generation remains weak. Varex’s quarter-ended 2026-07-03 financial statements reported nine-month operating cash flow of $3.4 million versus $33.8 million a year earlier, with inventories of $347.1 million versus $299.4 million. This limits the evidence for a strong standalone fallback if the agreement terminates; it does not establish a termination right.
Setup & Price Structure
The adjusted market close was $18.46 on 2026-09-11, against a supplied 52-week high of $18.58 and a three-month price increase of 67.2%. The contractual cash consideration remains $18.90 under the 2026-08-10 agreement. These observations describe a price below the acquisition consideration; they do not identify the market’s implied completion probability.
No moving-average series, volume history or current ownership-flow measurements accompany the 2026-09-11 snapshot. The sample is too small to support a claim about expanding participation, retail crowding or a new technical base. The $17.50 threshold remains the research invalidation published on 2026-09-03, rather than a newly verified support shelf.
Catalyst Calendar (next 30 days)
The 2026-09-08 proxy leaves the special-meeting date and Hart-Scott-Rodino antitrust filing and expiry dates blank. No dated merger catalyst is established inside the next 30 days. Preliminary proxy
- 2026-10-02 — Fiscal year end. The SEC’s 2026-09-08 filing metadata identifies this fiscal year-end calendar point. It is neither an earnings-release date nor a merger approval. SEC filing metadata
- 2027-05-10 — Initial outside date. The 2026-09-08 proxy permits extension to 2027-08-10 under specified unresolved-regulatory conditions. The initial date is therefore not an unconditional termination deadline. Preliminary proxy
What Would Change Our Mind
Loss of the published completion-price structure would invalidate the case: a daily close below $17.50 is the observable breach, retaining the threshold disclosed on 2026-09-03. That condition records failure of the price thesis without claiming that the transaction itself must then fail.
The former 2026-09-28 missing-proxy checkpoint is retired because the document arrived on 2026-09-08. Undisclosed antitrust dates establish uncertainty, not evidence of an adverse regulatory decision. Preliminary proxy
Correlation Notes
This is a single-company completion thesis. The 2026-08-10 agreement fixes cash consideration rather than an exchange ratio tied to Teledyne’s share price. Merger announcement filing No paired return series accompanies the 2026-09-11 price snapshot, so a measured correlation with medical technology equities, Teledyne or merger-arbitrage funds cannot be stated.
Notes
- All-cash deal signed 2026-08-10 at $18.90/share: upside is contractually capped absent a superior proposal.
- Merger agreement terms: $25.3M termination fee, 2027-05-10 outside date, no financing condition.
- Stockholder adoption requires a majority of shares outstanding, not merely a majority of votes cast.
- Closing conditions span HSR, foreign merger-control laws and foreign investment (FDI) laws, per the 2026-08-10 8-K.
- Varex cancelled its fiscal Q3 2026 earnings call because of the pending transaction; fiscal year ends early October.
- On completion the shares are delisted from Nasdaq and cease to exist as a traded instrument.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
ADPT
Adaptive Biotechnologies Corporation
clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22 sell-side band, running into a binary July 29 Q2 print — extension plus imminent earnings, not a clean fresh entry.
See also · stocks to watch